share_log

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $13 Price Target

Benzinga ·  Jun 25 18:36

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $13 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment